CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?

CorMedix surges on strong DefenCath uptake as sales climb while the Melinta acquisition expands and diversifies its commercial portfolio.

Zacks Investment Research • Dec 11, 2025

Does CorMedix (CRMD) Have the Potential to Rally 68.74% as Wall Street Analysts Expect?

The mean of analysts' price targets for CorMedix (CRMD) points to a 68.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Dec 9, 2025

CorMedix (CRMD) Upgraded to Strong Buy: Here's What You Should Know

CorMedix (CRMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research • Dec 8, 2025

New Strong Buy Stocks for December 8th

VFF, CRMD, AER, GM and FIVE have been added to the Zacks Rank #1 (Strong Buy) List on December 8, 2025.

Zacks Investment Research • Dec 8, 2025

Best Value Stocks to Buy for December 8th

GM, CRMD and AER made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 8, 2025.

Zacks Investment Research • Dec 8, 2025

Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?

CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.

Zacks Investment Research • Dec 5, 2025

CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating

CorMedix delivered strong Q3 results, with DefenCath outperforming expectations and near-term earnings power underestimated in prior analysis. CRMD raised FY25 guidance, but long-term risks remain due to TDAPA reimbursement changes, pricing pressure, and customer concentration. The Melinta acquisition and Rezzayo prophylaxis trial offer growth optionality, but Rezzayo's success is uncertain and pivotal for post-TDAPA prospects.

Seeking Alpha • Nov 14, 2025

CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations

CorMedix Inc. (NASDAQ:CRMD) reported third-quarter earnings of $1.26 per share on Wednesday, beating the consensus of 63 cents.

Benzinga • Nov 12, 2025

CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript

CorMedix Inc. ( CRMD ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Joseph Todisco - CEO & Director Elizabeth Masson-Hurlburt - Executive VP, Chief Operating Officer & Chief Integration Officer Susan Blum - EVP & Chief Financial Officer Conference Call Participants Daniel Ferry - Lifesci Advisors, LLC Leszek Sulewski - Truist Securities, Inc., Research Division Jason Butler - Citizens JMP Securities, LLC, Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Presentation Operator Good day, and welcome to the CorMedix Third Quarter 2025 Earnings and Corporate Update Conference Call.

Seeking Alpha • Nov 12, 2025

CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million ‒ ‒ Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million ‒ ‒ FY 2025 Pro Forma Net Revenue Guidance Raised to a Range of $390 to $410 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J.

GlobeNewsWire • Nov 12, 2025